Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma

BACKGROUND: Sorafenib is the only drug approved for the treatment of hepatocellular carcinoma (HCC). The bioenergetic propensity of cancer cells has been correlated to anticancer drug resistance, but such correlation is unclear in sorafenib resistance of HCC. METHODS: Six sorafenib-naive HCC cell li...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Y-C, Ou, D-L, Hsu, C, Lin, K-L, Chang, C-Y, Lin, C-Y, Liu, S-H, Cheng, A-L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553537/
https://www.ncbi.nlm.nih.gov/pubmed/23257894
http://dx.doi.org/10.1038/bjc.2012.559

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553537/
https://www.ncbi.nlm.nih.gov/pubmed/23257894
http://dx.doi.org/10.1038/bjc.2012.559

Ejemplares similares